Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ANPEP | P15144 | 2/20 | 0.40 |
| ▸ | LNPEP | Q9UIQ6 | 2/20 | 0.40 |
| ▸ | ENPEP | Q07075 | 14/20 | 0.39 |
| ▸ | CTSD | P07339 | 1/20 | 0.38 |
| ▸ | EDNRA | P25101 | 1/20 | 0.38 |
| ▸ | REN | P00797 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31318666 | 0.98 | ENPEP (0.41) | ANPEPLNPEPENPEP | |
| SCHEMBL30087273 | 0.94 | ENPEP (0.38) | ANPEPLNPEPENPEP | |
| SCHEMBL29615610 | 0.94 | CTSD (0.37) | ANPEPLNPEPENPEPCTSD | |
| SCHEMBL28101255 | 0.93 | ACE (0.38) | ANPEPLNPEPENPEPCTSD | |
| SCHEMBL30684916 | 0.93 | LNPEP (0.42) | ANPEPLNPEPENPEP | |
| SCHEMBL15011307 | 0.93 | ACE (0.42) | — | |
| SCHEMBL30874984 | 0.93 | ACE (0.42) | — | |
| SCHEMBL15011306 | 0.93 | ACE (0.42) | — | |
| SCHEMBL29625183 | 0.90 | ENPEP (0.39) | ENPEPCTSD | |
| SCHEMBL30684922 | 0.89 | CTSD (0.44) | ANPEPLNPEPCTSDEDNRAREN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210000972-A1 | NANOPARTICLES FOR SUSTAINED OPHTHALMIC DRUG DELIVERY AND METHODS OF USE | NEWPORT SCIENTIFIC, INC. | 2021-01-07 | — | — | US | disclosed |
| WO-2018140580-A1 | NANOPARTICLES FOR SUSTAINED OPHTHALMIC DRUG DELIVERY AND METHODS OF USE | 2C TECH CORP. (US) | 2018-08-02 | — | — | WO | disclosed |
| US-20180207293-A1 | NANOPARTICLES FOR SUSTAINED OPHTHALMIC DRUG DELIVERY AND METHODS OF USE | NEWPORT SCIENTIFIC, INC. | 2018-07-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180207293-A1 | NANOPARTICLES FOR SUSTAINED OPHTHALMIC DRUG DELIVERY AND METHODS OF USE | UACA, CRYAA, CRYAB | ANPEP 761/4885LNPEP 57/4885ENPEP 906/4885 |
| US-20210000972-A1 | NANOPARTICLES FOR SUSTAINED OPHTHALMIC DRUG DELIVERY AND METHODS OF USE | CHRNA1, CHRNB1, NPY1R | ANPEP 2274/4885LNPEP 1083/4885ENPEP 2379/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.